

Dear State Surveyor:

This report is designed to provide a comparative summary of treatment patterns and patient outcomes for End Stage Renal Disease (ESRD) patients in this state, as compared to all patients in the United States. The statistics reported here include dialysis patients treated during 2022-2025 in the chronic dialysis facilities in this state and are based primarily on data from the ESRD Quality Reporting System (EQRS), Medicare claims, and data collected for CMS. Selected statistics from this profile are summarized below and state-to-state comparisons of key statistics are provided in the *Maps and Tables of Key Statistics by State*.

ESRD CORE Pre-Survey Data Tool

For each facility with CCN xxxxxx in your state, key data elements from the DFR reviewed in the Core Survey Pre-survey Preparation task are reported in the QDFR_FY27_SEP_UPDATE_xxxxxx.pdf available on the secure Dialysis Reports website (www.DialysisData.org).

Selected highlights for this State are provided on the first few pages. For a complete description of the methods and data reported here please see the *Guide to the State Profiles for FY 2027*. The Guide is available on the Dialysis Data website at www.DialysisData.org. We hope this profile is of interest to you and is helpful in your survey efforts. We welcome your feedback on ways to improve future profiles.

What's New This Year

As part of a continuing effort to improve the quality and relevance of this report for your state, the following changes have been incorporated into the State Profile for FY 2027:

- COVID-19 patient counts, deaths, and hospitalizations among Medicare dialysis patients and Medicare nursing home dialysis patients previously reported in Tables C1 and C2 are no longer provided.
- COVID-19 adjustments were removed from the SMR (Table 3), STrR (Table 7), SHR for admissions, and SRR (Table 4) models.
- Time alive and out-of-the-hospital (AOH) statistics were added to Table 4. This measure combines mortality and hospitalization outcomes to present a metric that assesses the quality of patient care, while considering the complex inter-relationship between survival and hospital utilization. The AOH percentage is the proportion of patient-years at risk that patients were both alive and not in the hospital during a given time period, adjusted for patient characteristics. A higher AOH percentage indicates the positive outcome of patients in that dialysis facility having had more time alive and out of the hospital during the reporting period.

State Highlights

Patient Characteristics: On December 31st, 2025, 12.6% of patients in this state were treated in a nursing home during the year, compared to 13.6% nationally. See **Table 1** for detailed summaries of all patients treated during 2022-2025 in this state.

Form CMS-2728 collected data from 2,127 incident patients in this state in 2025. **Table 2** describes certain important characteristics of these patients at the time of their first outpatient dialysis session, including patients' demographics, medical coverage, primary cause of ESRD, modality, pre-treatment nephrological care, transplant options, and vascular access type. In 2025, the average age of patients in this state at incidence was 63 years, compared to the national average of 63 years. Among the incident patients in this state in 2025, 93.4% were informed of their transplant options, compared to 93.8% nationally. Also in 2025, 15.4% of incident patients in this state were not under the care of a nephrologist prior to ESRD therapy, compared to 14.9% nationally.

Mortality: There were 1,482 deaths among the patients treated in this state during 2025, while 1,533 would be expected based on their age, race, ethnicity, sex, diabetes status, duration of ESRD, nursing home status, BMI and comorbidities at incidence, as well as state population death rates. The Standardized Mortality Ratio (SMR) of observed to expected deaths is 0.96, which is 4% lower than expected. Of the deaths in this state in 2025, 29% were preceded by withdrawal from dialysis, compared to the national average of 24%. See **Table 3** of this profile for more detailed mortality statistics during 2022-2025 in this state.

First Year Mortality: There were 355 deaths among the incident patients treated in this state during 2024, while 356 would be expected based on their age, race, ethnicity, sex, diabetes status, nursing home status, BMI and comorbidities at incidence, as well as state population death rates. The First Year Standardized Mortality Ratio (SMR) of observed to expected deaths is 0.99, which agrees with the 3-year (2022-2024) national reference value of 1.0. Of the deaths among incident patients in this state in 2024, 28% were preceded by withdrawal from dialysis, compared to the national average of 24%. See **Table 3** of this profile for more detailed first year mortality statistics during 2022-2024 in this state.

Hospitalization: The Standardized Hospitalization Ratio (SHR) of observed to expected hospital admissions for patients in this state during 2025 is 0.98, indicating that these patients had 2% fewer admissions than expected based on characteristics of patients treated in this state. The Standardized Readmission Ratio (SRR) of observed to expected hospital readmissions in this state during 2025 is 1.03, indicating that these patients had 3% more readmissions than expected. See **Table 4** of this profile for additional hospitalization statistics during 2022-2025 in this state.

Transplantation: 322 patients under age 75 in this state during 2025 received their first transplant, while 319 would be expected based on the age of these patients. The Standardized Transplantation Ratio (STR) of observed to expected number of patients transplanted for this state is 0.98, which is 2% lower than expected. See **Table 5** of this profile for additional transplantation statistics during 2022-2025 in this state.

Kidney Transplant Waitlist for Prevalent Patients: The 2025 age-adjusted percent waitlisted in this state is 15.1%, which is 1.6% lower than the national adjusted percentage. See **Table 5** of this profile for additional transplant waitlist statistics during 2022-2025 in this state.

Kidney Transplant Waitlist for Incident Patients: The 2024 first-year Standardized Waitlist Ratio (FySWR) in this state is 1.07, which is 7% more patients waitlisted or living donor transplants than expected in this state. See **Table 5** of this profile for additional transplant waitlist statistics during 2022-2024 in this state.

Influenza Vaccination: On December 31, 2025, 77% of all patients treated in this state were vaccinated against influenza between August 1 and December 31, 2025, compared to 79% nationally. This difference is not statistically significant ($p \geq 0.05$) and is plausibly due to random chance. See **Table 6** of this profile for more information about vaccinated patients during 2022-2025 in this state.

Anemia Management: In 2025, 22.8% of eligible hemodialysis patient-months in this state had a hemoglobin value below 10 g/dL, compared to 23.0% nationally. In 2025, 20.6% of eligible peritoneal dialysis patient-months had a hemoglobin value below 10 g/dL, compared to 22.2% nationally. See **Table 7** of this profile for additional anemia management statistics in this state during 2022-2025.

Dialysis Adequacy: Of the eligible hemodialysis patient-months in this state in 2025, 96% had a Kt/V ≥ 1.2 , compared to 97% nationally. Of the eligible peritoneal dialysis patient-months in this state in 2025, 93% had a Kt/V ≥ 1.7 , compared to 93% nationally. See **Table 8** of this profile for more information on dialysis during 2022-2025 in this state.

Mineral Metabolism: In 2025, 18% of eligible patient-months in this state had a serum phosphorus value >7.0 mg/dL, compared to 18% nationally. Also in 2025, 1.4% of eligible patient-months in this state had a calcium uncorrected value >10.2 mg/dL, compared to 1.3% nationally. See **Table 9** of this profile for more mineral metabolism summaries in this state during 2022-2025.

Vascular Access: In 2025, 13% of the incident hemodialysis patients in this state had an arteriovenous (AV) fistula in use, compared to 12% in the nation. This state's 2025 Standardized Fistula Rate (SFR) for prevalent patients is 57%, which is 0% higher than the national SFR. Of the prevalent patients receiving hemodialysis treatment in this state, the long-term catheter rate was 20%, compared to 19% nationally. See **Table 10** of this profile for additional information about vascular access in this state during 2022-2025.

State Profile for FY 2027 for Dialysis Patients and Facilities

STATE SAMPLE

TABLE 1: Summaries for All Dialysis Patients Treated as of December 31st of each Year, 2022-2025^{*1}

Measure Name		This State				United States
		2022	2023	2024	2025	2025
1a	Patients treated on 12/31 of year (n)	8,333	8,339	8,320	8,259	462,513
1b	Average age (years)	62.2	62.3	62.5	62.5	62.8
1c	Age (% of 1a; sums to 100%)					
	< 18	0.2	0.2	0.2	0.3	0.2
	18-64	51.8	51.4	50.8	50.5	50.1
	65+	48.0	48.4	49.0	49.2	49.6
1d	Female (% of 1a)	42.0	41.9	42.1	41.9	41.7
1e	Race (% of 1a; sums to 100%)					
	African American	28.4	28.2	28.1	27.2	32.6
	Asian/Pacific Islander	11.2	11.2	11.3	10.8	6.7
	Native American	3.4	3.6	3.6	3.4	1.3
	White	56.5	56.1	55.5	52.9	52.8
	Other/Unknown/Missing	0.6	0.9	1.5	5.7	6.5
1f	Ethnicity (% of 1a; sums to 100%)					
	Hispanic	14.5	14.9	15.3	14.5	22.8
	Non-Hispanic	85.5	85.1	84.7	74.2	66.2
	Unknown	0.0	0.0	0.0	11.3	10.9
1g	Cause of ESRD (% of 1a; sums to 100%)					
	Diabetes	46.6	46.3	45.8	45.2	43.6
	Hypertension	26.7	26.9	27.3	27.6	31.4
	Glomerulonephritis	10.3	10.0	9.7	9.5	8.3
	Other/Unknown	16.1	16.4	16.9	17.3	16.4
	Missing	0.3	0.3	0.3	0.3	0.4
1h	Average duration of ESRD (years)	4.9	4.9	4.9	4.9	4.9
1i	Years since start of ESRD (% of 1a; sums to 100%)					
	<1	16.8	16.8	16.9	16.9	16.6
	1-2	18.2	17.9	17.9	17.9	17.6
	2-3	13.7	14.3	14.0	14.0	13.9
	3-6	25.6	25.3	25.6	25.6	26.0
	6+	25.7	25.7	25.6	25.6	25.9
1j	Nursing facility patients ^{**2} (% of 1a)	11.6	11.9	12.2	12.6	13.6
1k	Modality (% of 1a; sums to 100%)					
	In-center hemodialysis	83.7	83.1	82.9	82.8	83.0
	Home hemodialysis	3.3	3.7	4.1	4.4	4.2
	Continuous ambulatory peritoneal dialysis	1.5	1.7	1.8	1.9	1.7
	Continuous cycling peritoneal dialysis	11.0	11.1	10.9	10.5	10.8
	Other modality	0.5	0.4	0.4	0.4	0.4

n/a = not applicable.

[*1] See *Guide, Section IV* for detailed information regarding the summaries included in Table 1.

[*2] Includes patients who were treated at a nursing facility at any time during the year. The source of nursing facility history of patients is the Nursing Home Minimum Dataset.

State Profile for FY 2027 for Dialysis Patients and Facilities
STATE SAMPLE

TABLE 2: Characteristics of New Dialysis Patients, 2022-2025 (Form CMS-2728) ^{*1}

Measure Name		This State				United States
		2022	2023	2024	2025	
Patient Characteristics						2025
2a	Total number of patients with forms (n)	2,182	2,180	2,183	2,127	119,128
2b	Age (average years [0-95]) ^{*2}	62.5	62.7	62.8	62.6	63.1
2c	Female (% of 2a)	41.9	41.2	42.2	41.4	41.1
2d	Race (% of 2a; sums to 100%)					
	African American	23.7	23.3	23.0	17.8	21.4
	Asian/Pacific Islander	10.7	10.9	10.8	6.5	3.6
	Native American	3.0	3.3	3.0	2.0	0.8
	White	61.3	60.7	59.3	46.2	43.3
	Other/Unknown/Missing	1.3	1.8	4.0	27.5	30.8
2e	Hispanic (% of 2a)	13.4	13.4	14.2	6.0	9.3
2f	Primary cause of ESRD (% of 2a; sums to 100%)					
	Diabetes	47.4	47.5	46.5	45.1	42.3
	Hypertension	26.7	27.2	26.7	27.8	31.6
	Glomerulonephritis	7.3	6.8	6.6	6.7	5.4
	Other/Missing	18.6	18.6	20.1	20.4	20.6
2g	Medical Coverage (% of 2a; sums to 100%)					
	Employer group only	12.1	11.3	11.7	11.3	11.3
	Medicare only	42.9	43.0	39.5	40.2	41.1
	Medicaid only	16.0	16.5	16.9	16.0	14.9
	Medicare and Medicaid only	7.1	8.0	9.2	9.0	9.3
	Medicare and Other	9.5	9.9	11.0	11.5	9.8
	Other/Unknown	9.0	8.1	8.5	8.3	9.9
	None	3.4	3.2	3.3	3.7	3.9
2h	Body Mass Index					
	Male	28.1	27.9	27.8	27.9	27.5
	Female	28.9	28.9	28.6	28.5	28.3
2i	Employment (% of 2a)					
	Six months prior to ESRD treatment	37.8	38.7	37.2	37.3	37.7
	At first ESRD treatment	29.0	30.4	27.3	27.7	26.8
2j	Primary Modality (% of 2a; sums to 100%)					
	Hemodialysis	86.1	85.6	86.3	85.9	86.0
	CAPD/CCPD	13.9	14.4	13.6	14.0	14.0
	Other/Unknown/Missing	0.0	0.0	0.0	0.0	0.0
2k	Number of incident hemodialysis patients (n)	1,867	1,857	1,881	1,830	102,468
2l	Access used at first outpatient dialysis (% of 2k; sums to 100%)					
	Arteriovenous fistula	13.8	14.3	14.2	14.2	12.4
	Arteriovenous graft	2.9	2.7	2.9	2.6	3.0
	Catheter	83.0	82.6	82.5	82.6	84.1
	Other/Unknown/Missing	0.3	0.3	0.4	0.6	0.5
2m	Arteriovenous fistulae placed (% of 2k) ^{*3}	23.8	24.2	23.7	23.3	20.7
Average Lab Values Prior to Dialysis ^{*2}						
2n	Hemoglobin (g/dL [5-20])	9.3	9.3	9.4	9.4	9.4
2o	Serum Albumin (g/dL [0.8-6.0])	3.4	3.4	3.4	3.5	3.5
2p	Serum Creatinine (mg/dL [0-33])	6.7	6.6	6.4	6.4	6.3
2q	GFR (ml/min [0-30])	9.7	9.8	9.9	10.0	10.2

(continued)

State Profile for FY 2027 for Dialysis Patients and Facilities
STATE SAMPLE

TABLE 2 (continued): Characteristics of New Dialysis Patients, 2022-2025 (Form CMS-2728)^{*1}

		This State				United States
	Measure Name	2022	2023	2024	2025	
Care Prior to ESRD Therapy						
2r	Received ESA prior to ESRD (% of 2a)	17.1	17.2	18.0	18.8	18.0
2s	Pre-ESRD nephrologist care (% of 2a; sums to 100%)					
	No	17.0	16.7	16.8	15.4	14.9
	Yes, <6 months	18.0	18.4	17.6	17.6	18.9
	Yes, 6-12 months	18.4	18.0	18.5	17.7	17.8
	Yes, >12 months	32.8	32.5	33.1	34.4	29.6
	Unknown	13.8	14.3	14.0	14.8	18.6
2t	Informed of transplant options (% of 2a)	89.7	90.4	91.1	93.4	93.8
2u	Patients not informed of transplant options (n)	160	152	136	126	7,083
2v	Reason not informed (% of 2u; may not sum to 100%)					
	Medically unfit	39.4	40.8	26.9	5.3	6.3
	Unsuitable due to age	0.1	0.2	0.2	0.0	0.0
	Psychologically unfit	0.0	0.0	0.0	0.0	0.0
	Patient declined information	10.0	9.4	2.9	2.5	2.4
	Patient has not been assessed	55.0	54.9	33.4	0.1	0.0
Comorbid Conditions						
2w	Pre-existing Comorbidity (% yes of 2a)					
	Congestive heart failure	26.3	26.1	27.7	27.4	27.3
	Atherosclerotic heart disease	11.9	12.3	18.6	17.1	17.5
	Other cardiac disorder	19.8	20.7	24.9	24.8	24.1
	CVD, CVA, TIA	8.5	7.9	9.1	9.1	9.5
	Peripheral vascular disease	8.2	8.0	10.2	9.9	9.3
	History of hypertension	86.5	87.1	88.3	87.1	87.7
	Diabetes	64.1	64.5	64.5	63.4	62.5
	Diabetes on insulin	40.9	41.7	41.4	39.4	38.9
	COPD	7.9	7.9	8.5	8.3	8.0
	Current smoker	7.3	7.7	8.3	8.1	7.1
	Cancer	6.4	6.6	8.5	8.0	7.8
	Alcohol dependence	2.0	2.0	2.5	2.5	2.2
	Drug dependence	1.8	1.9	2.4	2.5	2.3
	Inability to ambulate	6.0	5.6	8.5	7.8	8.7
	Inability to transfer	3.0	2.7	4.7	4.3	5.3
2x	Average number of comorbid conditions	3.0	3.0	3.3	3.2	3.2
Standardized Modality Switch Ratio (SMoSR)						
		2022	2023	2024		2024
2y	Eligible patients (n)	2,085	2,041	2,030		113,802
2z	Patient-years at risk (n)	1,417	1,405	1,412		79,185
2aa	Number of modality switches (n)	180	178	175		9,776
2ab	Expected number of modality switches (n)	180	179	174		9,748
2ac	SMoSR (2aa/2ab) *A	1.00	0.99	1.00		1.00

n/a= not applicable.

[*A - *C] See **Appendix: Table Footnotes** on page 22.

[*1] See *Guide, Section V* for detailed information regarding the summaries included in Table 2. Race and ethnicity questions were removed from the CMS Form-2728 in 2025. As a result, the percent of patients with missing race and with missing ethnicity are higher in 2025 than in prior years.

[*2] For continuous variables, all summaries are computed based only on responses in range indicated in brackets for the variable.

[*3] Includes all patients with AV fistulae, regardless of whether they recieved their hemodialysis treatments using their fistulae.

TABLE 3: Mortality Summary for All Dialysis Patients (2022-2025) & New Dialysis Patients (2022-2024) ^{*1}

Measure Name		This State				United States
		2022	2023	2024	2025	
All Patients: Standardized Mortality Ratio (SMR)						2025
3a	Patients (n)	11,961	11,846	11,789	11,694	654,870
3b	Patient-years at risk (n)	8,420	8,357	8,353	8,302	464,916
3c	Deaths (n)	1,591	1,479	1,478	1,482	82,986
3d	Expected deaths (n)	1,650	1,539	1,538	1,533	85,837
3e	Withdrawal from dialysis prior to death (% of 3c)	26.9	27.1	27.6	28.8	24.3
3f	Deaths due to infections (% of 3c)	10.5	10.0	9.7	9.5	8.8
3g	Deaths due to cardiac causes (% of 3c)	42.8	44.4	44.0	43.4	45.2
3h	Deaths due to liver disease (% of 3c)	1.3	1.3	1.5	1.3	1.2
3i	Dialysis unrelated deaths (n; excluded from SMR)	10	9	9	8	454
3j	SMR (3c /3d) ^{*A, *2}	0.96	0.96	0.96	0.96	0.96
3k	P-value ^{*B}	.	.	.	.	n/a
New Patients: First-Year Standardized Mortality Ratio (FySMR)						2024
3l	Patients (n)	2,182	2,180	2,183		122,245
3m	Patient-years at risk (n)	1,956	1,956	1,956		109,515
3n	Deaths (n)	358	352	355		19,868
3o	Expected deaths (n)	357	350	356		19,928
3p	Withdrawal from dialysis prior to death (% of 3n)	27.2	27.2	27.9		24.3
3q	Deaths due to infections (% of 3n)	9.8	9.5	9.6		8.4
3r	Deaths due to cardiac causes (% of 3n)	38.8	39.1	37.7		39.6
3s	Deaths due to liver disease (% of 3n)	2.7	2.4	3.1		2.2
3t	FySMR (3n /3o) ^{*A, *2}	1.00	1.00	0.99		0.99
3u	P-value ^{*B}	.	.	.		n/a

n/a = not applicable.

[*A - *C] See **Appendix: Table Footnotes** on page 22.

[*1] See *Guide, Section VI* for detailed information regarding the summaries included in Table 3.

[*2] The SMRs (3j, 3t) are not shown if there are fewer than 3 expected deaths (3d,3o).

TABLE 4: Hospitalization Summary for Medicare Dialysis Patients, 2022-2025 ^{*1}

		This State				United States
Measure Name		2022	2023	2024	2025	2025
Medicare Dialysis Patients						
4a	Medicare dialysis patients (n)	9,406	9,223	9,226	9,148	512,275
4b	Patient-years at risk (n)	6,373	6,324	6,360	6,291	352,303
Standardized Hospitalization Ratio (SHR) for Days Hospitalized ^{*2}						
4c	Total days hospitalized (n)	72,165	70,518	72,447	75,474	4,226,519
4d	Expected days hospitalized (n)	76,722	74,679	76,335	78,949	4,421,124
4e	SHR for Days (4c/4d) ^{*A}	0.94	0.94	0.94	0.95	0.95
4f	P-value for SHR (Days) ^{*B}	0.066	0.058	0.056	.	n/a
Standardized Hospitalization Ratio (SHR) for Hospital Admissions ^{*2, *3}						
4g	Total admissions (n)	8,956	9,034	9,476	10,002	560,101
4h	Expected total admissions (n)	9,134	9,224	9,670	10,169	569,482
4i	SHR for Admissions (4g/4h) ^{*A}	0.98	0.97	0.97	0.98	0.98
4j	P-value for SHR (Admissions) ^{*B}	.	.	.	.	n/a
4k	Patients with septicemia (% of 4a)	11.7	11.8	12.0	12.3	13.4
4l	One day admissions (% of 4g)	8.5	8.7	8.0	8.2	7.8
4m	Average length of stay (days per admission)	8.1	7.9	7.8	7.6	7.5
4n	Admissions that originate in the ED (% of 4g)	80.5	81.2	81.9	82.4	84.8
Standardized Emergency Department Encounter Ratio (SEDR) ^{*2}						
4o	Emergency department (ED) events (n)	4,304	3,826	3,633	3,542	198,366
4p	Expected number of emergency department events (n)	4,347	3,873	3,679	3,595	201,304
4q	SEDR (4o/4p) ^{*A}	0.99	0.98	0.98	0.98	0.98
4r	P-value for SEDR ^{*B}	0.082	0.120	0.132	0.065	n/a
Standardized Ratio of ED Encounters Occurring within 30 Days of Hospital Discharge (ED30)						
4s	Index discharges (n)	3,623	3,346	3,226	3,252	182,110
4t	Total ED visits within 30 days of hospital discharge (n)	516	472	455	466	26,103
4u	Expected total ED visits within 30 days of hospital discharge (n)	469	426	409	420	23,500
4v	ED30 Ratio (4t/4u) ^{*A}	1.10	1.11	1.11	1.11	1.11
Standardized Readmission Ratio (SRR) ^{*2}						
4x	Index discharges (n)	7,811	7,970	8,341	8,807	493,169
4y	Total readmissions (n)	2,045	2,122	2,273	2,453	137,348
4z	Expected total readmissions (n)	1,964	2,039	2,202	2,379	133,233
4aa	SRR (4y/4z) ^{*A}	1.04	1.04	1.03	1.03	1.03

(continued)

TABLE 4 (continued): Hospitalization Summary for Medicare Dialysis Patients, 2022-2025^{*1}

Measure Name		This State				United States
		2022	2023	2024	2025	2025
Time Alive and Out of Hospital (AOH) ^{*4}						
4ab	Percent of time AOH (% of 4b)	89.0	89.7	89.7	89.4	89.2
	Percent of time lost due to death (% of 4b)	8.5	7.8	7.7	7.9	7.8
	Percent of time lost to hospitalizations (% of 4b)	2.5	2.5	2.5	2.7	3.0
4ac	Adjusted percent of time AOH	88.8	89.3	89.5	89.2	89.3

n/a = not applicable.

[*A - *C] See **Appendix: Table Footnotes** on page 22.

[*1] See *Guide, Section VII* for detailed information regarding the summaries included in Table 4. SEDR and ED30 statistics include only patients with Medicare as primary insurer and exclude patients with Medicare Advantage plans. All other summaries include patients with Medicare as primary insurer or with a Medicare Advantage plan.

[*2] SHRs and SEDR are not shown if there are less than five patient years at risk. SRR and ED30 ratios are not shown if fewer than 11 index discharges in the year. Adjusted percent of time AOH is not shown if there are less than 11 eligible patients.

[*3] Row 4k includes diagnoses in any position on a hospital inpatient claim.

[*4] In order to appropriately count time lost due to death for the AOH percentage, time at risk continues beyond a deceased patient's death date through the end of that calendar year.

TABLE 5: Transplantation and Waitlist Summary for All Dialysis Patients (2022-2025) & New Dialysis Patients (2022-2024) under Age 75 ^{*1}

Measure Name		This State				United States
		2022	2023	2024	2025	2025
Transplantation: All Transplants						2025
5a	Eligible patients (n)	9,506	9,338	9,214	9,054	507,026
5b	Transplants (n)	352	367	367	361	20,226
Transplantation: First Transplants						
5c	Eligible patients (n)	8,888	8,732	8,621	8,472	474,417
5d	Patient-years at risk (n)	6,269	6,170	6,116	6,023	337,311
5e	Actual first transplants (n)	316	327	329	322	18,019
5f	Expected first transplants (n)	308	320	324	319	17,857
5g	Standardized Transplantation Ratio (STR; 5e/5f)	1.00	0.98	1.02	0.98	1.00
5h	P-value ^{*B}	.	.	.	.	n/a
Dialysis Patients on the Waitlist						
5i	Eligible patients (n)	9,333	9,118	8,966	8,775	492,206
5j	Patient-months at risk (n) ^{*3}	78,579	77,324	76,174	75,038	4,207,510
5k	Patient-months on the waitlist (% of 5j) ^{*3}	15.2	15.0	15.0	15.3	16.9
5l	Patient-months on the waitlist by subgroup (%) ^{*C, *2}					
	Age < 40	23.5	23.1	23.8	24.7	26.7
	Age 40-74	14.3	14.0	14.0	14.2	15.8
	Male	16.2	15.9	16.1	16.5	18.2
	Female	13.7	13.5	13.5	13.6	15.0
	African American	15.4	14.7	14.7	14.7	15.7
	Asian/Pacific Islander	22.6	21.3	21.0	22.3	24.6
	Native American	9.4	10.0	11.2	10.9	10.4
	White, Hispanic	14.8	16.0	15.0	15.4	17.8
	White, Non-Hispanic	15.6	15.6	16.2	16.4	16.9
	Other/Unknown race	14.3	15.1	15.8	13.4	13.8
	Diabetes	12.4	12.5	12.6	12.9	14.5
	Non-diabetes	17.6	17.0	17.0	17.3	18.8
	Previous kidney transplant	26.7	26.2	25.3	25.1	27.7
	No previous kidney transplant	14.3	14.2	14.2	14.6	16.1
	<2 years since start of ESRD	12.8	13.0	13.4	13.8	14.3
	2-4 years since start of ESRD	19.4	19.1	19.2	19.7	21.7
	5+ years since start of ESRD	14.1	13.2	12.9	12.8	15.4
5m	Age-adjusted percentage of patient-months waitlisted	14.8	14.6	14.7	15.1	16.6
5n	Patient-months on the waitlist in active status (% of 5j) ^{*C}	8.5	8.5	8.4	8.7	10.2
5o	Age-adjusted % of patient-months waitlisted in active status	8.2	8.2	8.2	8.4	9.9
All Patients: Prevalent Standardized Waitlist Ratio (PSWR)						
5p	Eligible patients (n)	7,612	7,146	6,787	6,455	361,452
5q	Patient-years at risk (n)	5,504	5,102	4,847	4,625	259,003
5r	Waitlist events (n) ^{*3}	387	397	415	425	23,800
5s	Expected waitlist events (n) ^{*3}	382	390	411	422	23,608
5t	PSWR (5r/5s) ^{*A, *3}	1.01	1.02	1.01	1.01	1.01
5u	P-value for PSWR ^{*B}	.	.	.	.	n/a

(continued)

TABLE 5 (continued): Transplantation and Waitlist Summary for All Dialysis Patients (2022-2025) & New Dialysis Patients (2022-2024) under Age 75^{*1}

Measure Name		This State			United States
		2022	2023	2024	
New Dialysis Patients: First-Year Standardized Waitlist Ratio (FySWR)					2024
5v	Eligible Patients (n)	1,451	1,427	1,400	78,397
5w	Patient-years at risk (n)	1,301	1,280	1,255	70,265
5x	First waitlist events (n) ^{*3}	130	133	137	7,651
5y	Expected first waitlist events (n) ^{*3}	137	135	127	7,118
5z	FySWR (5x/5y) ^{*A, *3}	0.94	0.98	1.07	1.07
5aa	P-value for FySWR ^{*B}	0.119	.	0.148	n/a

n/a = not applicable.

[*A - *C] See **Appendix: Table Footnotes** on page 22.

[*1] See *Guide Section VIII* for detailed information regarding the transplant and waitlist summaries included in Table 5. Eligible patient-months (5j) include patients assigned to the facility on the last day of each month.

[*2] The waitlist percentage for each subgroup is calculated as a rate of waitlisted patient-months to patient-months at risk in each subgroup. A missing value indicates that there were no eligible patients in the subgroup.

[*3] An event is defined as a waitlisting or living-donor transplant. FySWR and PSWR are not shown if a facility has less than 2 expected waitlisted events or less than 11 eligible patients.

State Profile for FY 2027 for Dialysis Patients and Facilities
STATE SAMPLE

TABLE 6: Influenza Vaccination Summary All Dialysis Patients, Flu Seasons during August 2022-December 2025 ^{*1}

Measure Name		This State				United States
		2022	2023	2024	2025	
						2025
6a	Eligible patients on 12/31 (n)	8,843	8,834	8,830	8,735	489,171
6b	Patients excluded due to medical contraindication (n)	219	169	176	219	12,280
Full Flu Season (Aug. 1-Mar. 31 of following year)						2024
6c	Patients vaccinated (% of 6a)	82.2	80.5	78.7		79.8
6d	P-value ^{*2} (for 6c compared to U.S. value ^{*3})	0.041	0.036	0.030		n/a
6e	Reason for no vaccination (% of 6a)					
	Declined vaccination	7.3	8.3	11.4		12.2
	Other reason or vaccine data not available	10.5	11.2	9.9		8.0
Half Flu Season (Aug. 1-Dec. 31)						2025
6f	Patients vaccinated (% of 6a)	80.0	77.9	77.3	77.2	78.7
6g	P-value ^{*2} (for 6f compared to U.S. value ^{*4})	0.044	0.017	0.031	0.053	n/a
6h	Patients vaccinated by subgroup (%) ^{*5}					
	Medicare	80.8	78.8	78.0	78.1	79.4
	Medicare Advantage	79.8	80.0	78.3	78.0	80.6
	Medicare as primary insurer	80.0	77.9	77.0	77.1	78.0
	Non-Medicare	74.7	72.3	72.2	71.7	74.7
	Dual Medicare/Medicaid eligible	79.5	77.6	76.3	77.2	78.0
	Age < 18	60.2	58.9	60.0	60.9	61.4
	Age 18-39	70.9	68.2	66.8	68.7	69.8
	Age 40-64	78.0	75.3	74.6	74.2	75.6
	Age 65-74	82.0	80.5	79.1	79.1	80.8
	Age 75+	84.4	82.6	82.8	82.3	84.1
	Male	79.5	77.1	76.2	76.1	77.7
	Female	80.5	78.9	78.4	78.5	79.6
	African American	76.2	73.3	74.9	75.1	75.5
	Asian/Pacific Islander	84.3	83.2	83.0	82.5	86.0
	Native American	70.9	72.6	72.3	70.8	83.0
	White	79.6	77.3	77.9	77.0	80.5
	Other/unknown race	70.2	70.2	75.2	68.3	71.1
	Hispanic	81.8	79.2	80.4	80.8	84.1
	< 1 year since start of ESRD	72.0	70.4	70.3	70.5	71.6
	1-2 years since start of ESRD	80.0	77.3	76.3	76.1	77.5
	3+ years since start of ESRD	83.5	81.5	80.6	80.5	82.0

n/a = not applicable

[*1] See *Guide, Section X* for detailed information regarding the summaries included in Table 6. All Dialysis Patients are those treated on December 31st of the reporting year.

[*2] A p-value greater than or equal to 0.05 indicates that the difference between percent of patients vaccinated at the state and national percentage is plausibly due to random chance.

[*3] Compared to the U.S. value for that year and time period (08/01-03/31): 82% (2022), 80% (2023), 80% (2024).

[*4] Compared to the U.S. value for that year and time period (08/01-12/31): 81% (2022), 79% (2023), 78% (2024), 79% (2025).

[*5] A missing value indicates that there were no eligible patients in the subgroup.

TABLE 7: Anemia Management Summaries for Adult Dialysis Patients, 2022-2025 ^{*1}

		This State				United States
Measure Name		2022	2023	2024	2025	2025
Hemoglobin and ESA for Adult Hemodialysis (HD) Patients						
7a	Eligible HD patients (n)	9,199	9,083	9,061	9,050	499,834
7b	Eligible HD patient-months (n) ^{*C}	84,726	83,928	83,560	83,731	4,688,929
7c	Average hemoglobin (g/dL) (average of 7b)	10.7	10.7	10.7	10.8	10.8
7d	Hemoglobin categories (% of 7b; sums to 100%)					
	<10 g/dL	23.1	22.8	22.9	22.8	23.0
	10-<11 g/dL	33.4	32.5	32.8	32.3	32.8
	11-12 g/dL	27.6	28.8	28.7	28.4	29.2
	>12 g/dL	12.2	12.9	12.8	13.1	12.8
	Missing/Out of range	3.6	3.0	2.8	3.4	2.1
7e	ESA prescribed (% of 7b)	73.6	74.1	74.4	73.1	76.4
Hemoglobin and ESA for Adult Peritoneal Dialysis (PD) Patients						
7f	Eligible PD patients (n)	1,548	1,564	1,549	1,506	80,387
7g	Eligible PD patient-months (n) ^{*C}	12,363	12,538	12,619	12,234	660,621
7h	Average hemoglobin (g/dL) (average of 7g)	11.0	11.0	11.0	11.0	11.0
7i	Hemoglobin categories (% of 7g; sums to 100%)					
	<10 g/dL	21.0	20.8	21.0	20.6	22.2
	10-<11 g/dL	27.3	26.5	27.2	27.3	28.3
	11-12 g/dL	25.9	26.7	26.6	26.7	26.7
	>12 g/dL	20.7	21.8	21.3	21.0	19.9
	Missing/Out of range	5.1	4.3	3.9	4.4	2.9
7j	ESA prescribed (% of 7g)	52.3	52.2	52.3	51.3	54.3
Standardized Transfusion Ratio (STrR)						
7k	Adult Medicare patients (n)	4,214	3,721	3,503	3,345	187,319
7l	Patient-years at risk (n)	2,415	2,119	1,968	1,839	102,968
7m	Total transfusions (n)	775	678	612	587	32,865
7n	Expected total transfusions (n)	814	712	645	616	34,471
7o	STrR(7m/7n) ^{*A, *1}	0.95	0.95	0.94	0.95	0.95
7p	P-value ^{*B}	.	.	0.110	.	n/a

n/a = not applicable.

[*A - *C] See **Appendix: Table Footnotes** on page 22.

[*1] See *Guide, Section XI* for detailed information regarding the summaries included in Table 7. Transfusion summaries include adult Medicare dialysis patients only and not shown if there are fewer than 10 patient-years at risk (7o).

TABLE 8: Dialysis Adequacy Summaries for All Dialysis Patients, 2022-2025^{*1}

		This State				United States
Measure Name		2022	2023	2024	2025	2025
Adult Hemodialysis (HD) Adequacy						
8a	Eligible HD patients (n)	9,199	9,083	9,061	9,050	499,834
8b	Eligible HD patient-months (n) ^{*C}	84,726	83,928	83,560	83,731	4,688,929
8c	Average serum albumin (g/dL) (average of 8b)	3.9	3.9	3.9	3.9	3.9
8d	Serum albumin categories (% of 8b; sums to 100%)					
	< 3.0 g/dL	2.0	1.8	1.8	1.6	1.6
	3.0-<3.5 g/dL	8.5	8.2	8.3	7.6	7.3
	3.5-<4.0 g/dL	38.8	40.3	40.4	37.4	36.6
	>=4.0 g/dL	47.5	47.4	47.5	50.1	50.6
	Missing	3.2	2.4	2.0	3.3	3.9
8e	Ultrafiltration rate average (ml/kg/hr) (average of 8b)	7.7	7.7	7.6	7.5	7.5
8f	Ultrafiltration rate categories (% of 8b; sums to 100%)					
	<=13 (ml/kg/hr)	86.6	86.9	87.7	88.3	88.7
	>13 (ml/kg/hr)	7.8	7.7	7.3	6.9	7.0
	Out of Range (>=20 ml/kg/hr)	2.4	2.6	2.5	2.4	2.1
	Missing	3.2	2.8	2.4	2.4	2.2
8g	Eligible HD Kt/V patients (n) ^{*2}	8,741	8,608	8,549	8,498	469,515
8h	Eligible HD Kt/V patient-months (n) ^{*C, *2}	79,245	78,410	77,614	77,500	4,340,003
8i	Average Kt/V (average of 8h) ^{*2}	1.6	1.6	1.6	1.6	1.6
8j	Kt/V categories (% of 8h; sums to 100%) ^{*2}					
	<1.2	1.9	1.6	1.7	1.9	1.7
	1.2-<1.8	71.6	69.8	72.0	72.5	72.4
	>=1.8	24.7	27.1	24.9	24.0	24.3
	Missing/Out of range	1.8	1.5	1.4	1.7	1.6
Adult Peritoneal Dialysis (PD) Adequacy						
8k	Eligible PD patients (n)	1,548	1,564	1,549	1,506	80,387
8l	Eligible PD patient-months (n) ^{*C}	12,363	12,538	12,619	12,234	660,621
8m	Average Weekly Kt/V (average of 8l) ^{*2}	2.2	2.2	2.2	2.2	2.2
8n	Weekly Kt/V categories (% of 8l; sums to 100%) ^{*2}					
	<1.7	5.1	4.9	4.7	4.7	4.9
	1.7-<2.5	68.8	68.0	68.8	68.8	68.5
	>=2.5	23.3	24.4	24.0	24.4	24.1
	Missing/Out of range	2.8	2.6	2.5	2.1	2.5
8o	Average serum albumin (g/dL) (average of 8l)	3.7	3.7	3.7	3.7	3.7
8p	Serum Albumin Categories (% of 8l; sums to 100%)					
	< 3.0 g/dL	6.0	5.3	5.2	4.9	4.8
	3.0-<3.5 g/dL	21.2	20.3	20.7	19.7	19.4
	3.5-<4.0 g/dL	42.8	44.8	44.9	42.7	43.0
	>=4.0 g/dL	26.8	26.9	26.7	29.3	29.6
	Missing	3.2	2.7	2.5	3.3	3.2

(continued)

TABLE 8 (continued): Dialysis Adequacy Summaries for All Dialysis Patients, 2022-2025^{*1}

Measure Name		This State				United States
		2022	2023	2024	2025	2025
Pediatric Kt/V ^{*2}						
8q	Eligible Pediatric HD patients (n)	16	17	16	17	821
8r	Eligible Pediatric HD patient-months (n) ^{*C}	107	113	111	115	5,654
8s	Average Kt/V (average of 8r)	1.8	1.7	1.7	1.7	1.7
8t	Kt/V categories (% of 8r; sums to 100%)					
	<1.2	2.4	2.4	2.7	2.0	3.4
	1.2-<1.8	52.7	55.8	56.1	58.2	58.2
	>= 1.8	38.4	30.6	32.2	33.1	29.9
	Missing/Out of Range	6.5	11.2	9.1	6.8	8.6
8u	Eligible Pediatric PD Patients (n)	20	19	19	18	820
8v	Eligible Pediatric PD patient-months (n) ^{*C}	150	144	135	129	6,058
8w	Average Weekly Kt/V (average of 8v)	2.4	2.4	2.4	2.4	2.4
8x	Weekly Kt/V categories (% of 8v; sums to 100%)					
	<1.7	13.9	12.9	11.7	14.3	12.8
	1.7-<2.5	45.9	46.4	46.6	43.4	46.8
	>=2.5	26.9	30.8	31.6	34.3	31.9
	Missing/Out of Range	13.3	9.9	10.1	7.9	8.5

n/a = not applicable.

[*A - *C] See **Appendix: Table Footnotes** on page 22.

[*1] See *Guide, Section XII* for detailed information regarding the summaries included in Table 8.

[*2] Kt/V summaries are supplemented with Medicare claims if missing in EQRS. HD Kt/V summaries are restricted to patients who dialyze thrice weekly. See section of Guide titled "*Determination of Thrice Weekly Dialysis*" for more information. The most recent value over a 4-month period is selected for PD Kt/V.

TABLE 9: Mineral Metabolism Summaries for All Adult Dialysis Patients, 2022-2025 ^{*1}

Measure Name		This State				United States
		2022	2023	2024	2025	2025
9a	Eligible adult patients (n)	10,403	10,301	10,276	10,227	564,451
9b	Eligible adult patient-months (n) ^{*C}	96,901	96,260	95,964	95,767	5,362,962
9c	Average Phosphorus (mg/dL) ^{*2}	5.5	5.5	5.6	5.6	5.6
9d	Phosphorus categories (% of 9b; sums to 100%) ^{*2}					
	<3.5 mg/dL	7.4	7.3	7.0	6.9	7.0
	3.5-4.5 mg/dL	22.3	21.9	21.3	20.6	20.8
	4.6-5.5 mg/dL	27.4	26.8	26.5	25.2	25.7
	5.6-7.0 mg/dL	22.7	23.9	24.6	25.3	25.5
	>7.0 mg/dL	15.8	16.4	17.2	17.7	17.8
	Out of Range (<0.01 mg/dL or >20 mg/dL)	0.0	0.0	0.0	0.0	0.0
	Missing	4.4	3.7	3.5	4.3	3.2
9e	Average Calcium Uncorrected (mg/dL)	8.9	8.9	8.9	8.9	8.9
9f	Calcium Uncorrected categories (% of 9b; sums to 100%)					
	<8.4 mg/dL	18.8	20.0	19.2	19.6	19.8
	8.4-10.2 mg/dL	76.9	76.3	77.3	75.9	75.9
	>10.2 mg/dL	1.2	1.1	1.3	1.4	1.3
	Out of Range (<0.01 mg/dL or >20 mg/dL)	0.0	0.0	0.0	0.0	0.0
	Missing	3.1	2.5	2.2	3.0	3.0
9g	Average uncorrected calcium > 10.2 mg/dL (%) ^{*3}	2.2	1.9	1.8	1.4	1.2

n/a = not applicable.

[*A - *C] See **Appendix: Table Footnotes** on page 22.

[*1] See *Guide, Section XIII* for detailed information regarding the summaries included in Table 9.

[*2] Eligible patients included in the phosphorous summaries differ slightly from what is reported in 9b since it includes patient-months within the first 90 days of ESRD.

[*3] Hypercalcemia is averaged from uncorrected serum or plasma calcium values over a rolling 3-month period. Eligible patients included in the hypercalcemia summary differs slightly from what is reported in 9b since patients must be 18 as of the first day of the 3-month period.

TABLE 10: Vascular Access Information for all Adult Dialysis Patients and Access-Related Infection Summaries for all Medicare Patients, 2022-2025^{*1}

Measure Name		This State				United States
		2022	2023	2024	2025	2025
Vascular Access ^{*2}						
10a	Prevalent adult hemodialysis (HD) patients (n)	9,688	9,524	9,492	9,445	521,679
10b	Prevalent adult hemodialysis patient months (n) ^{*C}	88,332	87,014	86,430	86,340	4,835,051
10c	Vascular access type in use (% of 10b; sums to 100%)					
	Arteriovenous fistula	60.3	59.7	58.8	57.5	57.3
	Arteriovenous graft	15.4	15.2	15.5	15.6	16.7
	Catheter	22.1	23.3	24.3	25.6	25.0
	Other/Missing	2.2	1.7	1.5	1.3	1.0
10d	Standardized Fistula Rate (SFR) ^{*3}	59.4	58.9	58.1	56.8	56.7
10e	Long-Term Catheter Rate ^{*4}	17.0	17.8	18.5	19.7	19.1
Vascular Access at First Treatment						
10f	Incident adult hemodialysis patients (n)	1,884	1,870	1,897	1,854	103,828
10g	Vascular access type in use (% of 10f; sums to 100%)					
	Arteriovenous fistula	13.6	13.8	13.6	13.3	11.7
	Arteriovenous graft	3.2	3.3	3.4	3.0	3.4
	Catheter	81.5	81.4	81.8	80.0	81.4
	Other/Missing	1.8	1.5	1.2	3.6	3.6
10h	Arteriovenous fistulae in placed (% of 10f) ^{*5}	14.5	14.7	14.4	14.0	12.2
Infection: Peritoneal dialysis (PD)						
10i	Eligible PD patients (n)	779	728	689	660	35,617
10j	Eligible PD patient-months (n) ^{*C}	5,337	4,979	4,779	4,499	242,930
10k	PD catheter infection rate per 100 PD patient-months	2.8	2.7	2.6	2.6	2.7
10l	P-value ^{*6} of 10k (compared to U.S. value ^{*7})	0.156	0.157	0.157	0.177	n/a

n/a = not applicable

[*A - *C] See **Appendix: Table Footnotes** on page 22.

[*1] See *Guide, Section XIV* for detailed information regarding the summaries included in Table 10.

[*2] Patient months with a catheter that have limited life expectancy, including under hospice care in the current reporting month, or with metastatic cancer, end stage liver disease, coma or anoxic brain injury in the past 12 months, were excluded.

[*3] Includes patients with an autogenous arteriovenous (AV) fistula as the sole means of vascular access. SFR is calculated as an adjusted rate of AV fistula in use reported in 10c.

[*4] Includes patients using a catheter continuously for three months or longer. Patients with other or missing access types (10c) are also counted as catheter in use in the numerator.

[*5] Includes all patients with fistulae, regardless of whether or not they received their hemodialysis treatments using their fistulae.

[*6] A p-value greater than or equal to 0.05 indicates the differences between the percent of patients with infection at the facility and national percentage is plausibly due to random change.

[*7] Compared to U.S. value for that year: 2.66 (2022), 2.69 (2023), 2.64 (2024), and 2.69 (2025).

TABLE 11: Comorbidities Reported on Inpatient Medicare Claims for Medicare Dialysis Patients Treated as of December 31st of Each Year, 2022-2025^{*1}

Measure Name		This State				United States
		2022	2023	2024	2025	2025
11a	Medicare dialysis patients on 12/31(n)	6,421	6,369	6,405	6,335	354,749
11b	Comorbidity (% yes of 11a)					
	Infections					
	AIDS/HIV positive	0.6	0.5	0.6	0.6	0.8
	Intravascular/implanted device-related ^{*2}	4.4	4.7	4.6	4.7	4.9
	Hepatitis B	0.4	0.4	0.4	0.4	0.5
	Hepatitis other	1.4	1.2	1.2	1.2	1.3
	Metastatic	1.4	1.5	1.6	1.7	1.7
	Pneumonia	3.2	3.5	3.6	3.9	4.2
	Tuberculosis	0.2	0.2	0.2	0.3	0.3
	Other	23.9	22.1	21.9	21.7	22.9
	Cardiovascular					
	Cardiac arrest	0.8	0.8	0.8	0.9	1.0
	Cardiac dysrhythmia	17.6	18.2	19.1	20.3	21.4
	Cerebrovascular disease	6.2	6.6	7.1	7.3	8.5
	Congestive heart failure	28.1	29.2	30.4	32.1	34.4
	Ischemic heart disease	23.7	24.0	24.8	26.0	28.3
	Myocardial infarction	7.3	7.7	8.2	8.8	9.6
	Peripheral vascular disease ^{*3}	14.7	15.2	15.8	16.8	18.8
	Other					
	Alcohol dependence	1.4	1.5	1.5	1.6	1.5
	Anemia	2.9	2.9	3.1	3.2	3.5
	Cancer	3.2	3.4	3.5	3.8	4.1
	Chronic obstructive pulmonary disease	13.4	13.7	14.5	15.4	15.9
	Diabetes	34.0	34.7	35.3	36.7	38.7
	Drug dependence	1.2	1.2	1.3	1.4	1.4
	Gastrointestinal tract bleeding	2.7	2.7	3.0	3.3	3.5
	Hyperparathyroidism	19.1	20.3	21.4	22.7	23.6
11c	Average number of comorbid conditions	2.1	2.2	2.2	2.3	2.5

n/a = not applicable.

[*1] See *Guide, Section XV* for detailed information regarding the summaries included in Table 11. Based on patients with Medicare as primary insurer on 12/31 each year.

[*2] This category includes bloodstream and other infections related to intravascular access and other implanted devices, not limited to dialysis access.

[*3] Peripheral vascular disease includes venous, arterial and nonspecific peripheral vascular diseases.

State Profile for FY 2027 for Dialysis Patients and Facilities
STATE SAMPLE

TABLE 12: Selected Summaries for Nursing Home (NH) Patients, 2022-2025 ^{*1}

Measure Name		This State				United States
		2022	2023	2024	2025	2025
Patient Characteristics						
12.1a	Patients treated on 12/31 (n)	1,098	1,107	1,153	1,143	62,934
12.1c	Age (% of 12.1a; sums to 100%)					
	18-64	33.7	33.9	34.1	32.2	31.9
	65+	66.3	66.1	65.9	67.8	68.1
12.1d	Female (% of 12.1a)	47.5	49.7	48.6	48.2	47.1
12.1e	Race (% of 12.1a; sums to 100%)					
	African American	29.3	29.2	29.2	28.8	36.3
	Asian/Pacific Islander	6.0	7.9	5.9	5.8	4.4
	Native American	3.0	3.1	3.6	3.4	1.2
	White	61.4	59.3	60.4	58.5	54.0
	Other/Unknown/Missing	0.4	0.6	0.9	3.4	4.2
12.1f	Ethnicity (% of 12.1a; sums to 100%)					
	Hispanic	10.2	10.5	11.6	9.6	14.0
	Non-Hispanic	89.8	89.5	88.3	76.3	71.5
	Unknown	0.0	0.0	0.1	14.0	14.5
12.1g	Cause of ESRD (% of 12.1a; sums to 100%)					
	Diabetes	55.9	56.5	54.9	55.2	50.9
	Hypertension	25.2	24.2	24.7	24.3	29.3
	Glomerulonephritis	4.8	5.0	4.9	5.5	4.2
	Other	13.8	14.2	15.3	14.8	15.1
	Unknown/Missing	0.2	0.1	0.2	0.3	0.4
12.1i	Years since start of ESRD (% of 12.1a; sums to 100%)					
	< 1	22.3	20.5	22.3	20.0	20.8
	1-2	15.8	15.1	16.4	15.6	15.4
	2-3	11.6	13.2	11.8	13.6	12.3
	3-6	25.7	23.9	24.3	26.5	25.5
	6+	24.5	27.3	25.2	24.3	25.9
12.1k	Modality (% of 12.1a; sums to 100%)					
	In-center hemodialysis	93.6	92.5	92.1	91.3	89.4
	Home hemodialysis	3.2	4.4	5.1	5.7	7.6
	Continuous ambulatory peritoneal dialysis	0.1	0.3	0.3	0.2	0.3
	Continuous cycling peritoneal dialysis	2.1	2.2	1.8	2.1	2.0
	Other modality	0.9	0.7	0.7	0.7	0.8

(continued)

TABLE 12 (continued): Selected Summaries for Nursing Home (NH) Patients, 2022-2025 ^{*1}

		This State				United States
Measure Name		2022	2023	2024	2025	2025
Characteristics of New Dialysis Patients						
12.2a	Total number of patients with forms (n)	436	452	441	439	23,704
12.2g	Medical coverage (% of 12.2a; sums to 100%)					
	Employer group only	2.7	2.3	2.7	3.9	2.3
	Medicare (alone or combined w/ other insurance)	83.1	82.9	82.8	80.2	82.6
	Medicaid only	9.7	10.5	9.9	11.9	9.9
	Other/Unknown/None	4.5	4.3	4.5	3.9	5.2
12.2k	Number of incident hemodialysis patients (n)	446	464	450	450	24,287
12.2l	Access used at first outpatient dialysis (% of 12.2k; sums to 100%)					
	Arteriovenous fistula	8.0	7.7	7.1	7.3	6.0
	Arteriovenous graft	1.9	1.9	2.1	2.0	2.5
	Catheter	87.8	87.7	88.4	86.8	88.6
	Other/Unknown/Missing	2.3	2.7	2.5	3.9	2.9
12.2m	Arteriovenous fistulae placed (% of 12.2k)	16.9	16.8	15.9	15.0	12.7
12.2s	Pre-ESRD nephrologist care (% of 12.2a; sums to 100%)					
	No	18.7	14.9	18.6	14.3	15.3
	Yes, < 6 months	20.2	22.7	21.5	23.4	22.5
	Yes, 6-12 months	16.3	16.8	16.0	16.3	15.8
	Yes, > 12 months	25.0	25.4	24.1	26.8	20.9
	Unknown	19.8	20.2	19.6	19.0	25.3
12.2t	Informed of transplant options (% of 12.2a)	84.9	87.1	86.4	91.0	90.8
Mortality summary for all NH dialysis patients						
12.3a	Patients (n)	1,972	2,005	2,048	2,070	140,569
12.3b	Patient-years at risk (n)	1,178.4	1,203.2	1,230.8	1,240.8	73,126.7
12.3c	Deaths (n)	488	483	492	504	31,362
12.3d	Expected deaths (n)	424.1	415.6	423.3	426.0	24,698.4
12.3c/12.3b	Death Rate (per 100 PYs at risk)	43.8	38.1	38.6	39.7	42.9
12.3j	Standardized Mortality Ratio (12.3c/12.3d)	1.15	1.16	1.16	1.18	1.27
12.3e	Withdrawal from dialysis prior to death (% of 12.3c)	32.6	33.9	33.8	33.8	26.7
Hospitalization summary for NH Medicare dialysis patients						
12.4a	Medicare dialysis patients (n)	1,752	1,774	1,828	1,854	124,902
12.4b	Patient-years at risk (n)	1,021.6	1,042.8	1,075.3	1,086.7	63,587.0
12.4g	Total admissions (n)	2,994	3,103	3,286	3,543	212,435
12.4h	Expected total admissions (n)	1,976.5	2,080.9	2,210.2	2,368.7	137,559.3
12.4g/12.4b	Hospitalization Rate (per 100 PYs at risk)	285.8	272.4	293.4	301.6	334.1
12.4i	Standardized Hospitalization Ratio (12.4g/12.4h)	1.51	1.49	1.49	1.50	1.54
	Diagnoses associated with hospitalization (% of 12.4a)					
	Septicemia	22.0	25.2	23.7	24.9	23.5
	Acute myocardial infarction	11.7	11.6	12.7	14.7	13.0
	Congestive heart failure	46.5	45.7	47.5	50.4	47.5
	Cardiac dysrhythmia	34.1	35.7	33.8	35.8	33.9
	Cardiac arrest	3.4	3.3	3.4	3.9	4.0

(continued)

TABLE 12 (continued): Selected Summaries for Nursing Home (NH) Patients, 2022-2025^{*1}

Measure Name		This State				United States
		2022	2023	2024	2025	2025
Comorbidities reported on Medicare claims						
12.11a	Medicare dialysis patients on 12/31 (n)	925	947	984	993	58,367
12.11b	Comorbidity (% yes of 12.11a)					
Infections						
	AIDS/HIV positive	0.8	0.7	0.9	0.8	1.1
	Intravascular/implanted device-related	8.3	9.0	8.3	8.3	8.8
	Hepatitis B	0.6	0.6	0.6	0.6	0.9
	Hepatitis other	2.7	2.5	2.3	2.4	2.8
	Metastatic	4.3	3.9	4.4	5.0	4.9
	Pneumonia	8.6	8.6	9.1	10.3	11.8
	Tuberculosis	0.3	0.3	0.2	0.4	0.4
	Other	46.7	45.0	43.7	46.0	47.3
Cardiovascular						
	Cardiac arrest	2.0	2.1	1.9	2.2	2.7
	Cardiac dysrhythmia	35.8	39.0	37.7	39.1	42.4
	Cerebrovascular disease	17.0	17.4	17.8	20.6	21.5
	Congestive heart failure	52.4	54.5	54.3	58.6	60.9
	Ischemic heart disease	42.5	44.5	43.1	46.6	49.2
	Myocardial infarction	13.6	15.1	14.7	16.0	18.3
	Peripheral vascular disease	32.4	34.4	33.4	36.6	39.1
Anemia						
12.7b	Eligible adult HD patient-months (n) ^{*C}	12,620	12,889	13,134	13,324	746,169
12.7d	Hemoglobin (HD) < 10 g/dL (% of 12.7b)	29.3	29.3	29.3	29.3	30.9
12.7e	ESA prescribed (% of 12.7b)	78.3	80.2	80.6	78.4	80.0
12.7f	Eligible adult PD patients (n)	80	83	83	85	4,706
12.7g	Eligible adult PD patient-months (n) ^{*C}	453	476	485	495	27,702
12.7i	Hemoglobin (PD) < 10 g/dL (% of 7g)	27.0	28.5	25.7	28.6	29.6
12.7j	ESA prescribed (% of 7g)	56.0	57.0	54.7	55.3	56.5
Dialysis Adequacy^{*2}						
12.8b	Eligible adult HD Kt/V patient-months (n) ^{*C}	12,029	12,321	12,479	12,604	705,840
12.8j	Kt/V (HD) < 1.2 (% of 12.8b)	2.3	2.0	1.9	2.3	2.5
12.8k	Eligible adult PD Kt/V patients (n)	80	83	83	85	4,706
12.8l	Eligible adult PD Kt/V patient-months (n) ^{*C}	453	476	485	495	27,702
12.8n	Kt/V (PD) < 1.7 (% of 12.8l)	8.4	8.6	8.7	8.0	8.6
Vascular Access^{*3}						
12.10b	Prevalent adult hemodialysis patient months (n) ^{*C}	13,153	13,087	13,217	13,317	745,731
12.10c	Arteriovenous fistula in use (% of 12.10b)	47.8	48.8	47.9	47.6	46.8
12.10e	Long-Term Catheter Rate (LTCR)	22.8	23.3	23.9	24.4	24.3

n/a = not applicable; Kt/V: K = dialyzer clearance of urea; t = dialysis time; V = patient's total body water.

[*1] See *Guide, Section XVI* for detailed information regarding the summaries included in Table 12.

[*2] Kt/V summaries are supplemented with Medicare claims if missing in EQRS. HD Kt/V summaries are restricted to patients who dialyze thrice weekly. See section of *Guide* titled "*Determination of Thrice Weekly Dialysis*" for more information. PD Kt/V summaries select the most recent value collected within 4 months of the reporting month.

[*3] Patient months with a catheter that have limited life expectancy, including under hospice care in the current reporting month, or with metastatic cancer, end stage liver disease, coma or anoxic brain injury in the past 12 months, were excluded. Other or missing access types are counted as catheter in use in the numerator. LTCR includes patients using a catheter continuously for three months or longer.

Appendix: Table Footnotes

This appendix provides information that applies to multiple tables.

[*A] This value is the ratio of observed events to expected events.

[*B] Ratios within the range 0.95 to 1.05 will not have a p-value. A p-value ≥ 0.05 indicates that the ratio is >1.05 or <0.95 plausibly due to random chance.

[*C] A patient may be counted up to 12 times per year.